AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Catana Capital: New collaboration with Life Science AI pioneer Innoplexus
Catana Capital partners with a leading provider of AI solutions in the Life Science sector
Frankfurt am Main, December 16, 2019: As a pioneer in the application of Big Data and AI for quantitative asset management, Catana Capital is always open to collaborate with other innovators in the space in order to develop new innovative investment strategies. After a successful first year of the Data Intelligence Fund and the recent launch of overlay strategies for institutional investors, Catana Capital has now partnered with Innoplexus, a leading provider of artificial intelligence solutions in the Life Science sector.
Innoplexus has proven to provide deep insights into the Life Sciences data universe and especially the assessment of outcomes of clinical trials, which, combined with Catana Capital“s know how and experience in quantitative asset management, will form the basis for a successful joint venture. Innoplexus“ proprietary use of artificial intelligence and machine learning fits perfectly into Catana Capital“s strategy to further scale its revolutionary new investment strategy based on independent trading signals in the area of European pharmaceutical equities, where both companies will work together on an exclusive basis.
Catana Capital“s innovative Data Intelligence Fund (ISIN: DE000A2H9A76) has met all expectations since its launch and the additional approach into the pharma sector is a solid diversification within the fund which will further contribute to its success.
Catana Capital GmbH is a financial services institution licensed in compliance with Section 32 of the German Banking Act (KWG) and domiciled in Frankfurt am Main. The FinTech was founded in August 2015 and manages the Data Intelligence Fund, a public fund based entirely on big data and artificial intelligence. Catana Capital sees itself as a pioneer in the development of new approaches to asset management and offers innovative investment products for private investors and institutional clients.
Further information can be found at https://catanacapital.com/
Originally published on Press Network.
Featured News
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany,…